Form 4: Heartflow Director Julie Cullivan Acquires Stock Options

Heartflow, Inc. Director Julie A. Cullivan reported the acquisition of stock options on June 16, 2026, as part of her compensation.

Summary

• Julie A. Cullivan, a Director at Heartflow, Inc., acquired stock options on June 16, 2026.
• The transaction involved 16,075 stock options with an exercise price of $32.05.
• These options are set to vest in full on the earlier of the day prior to Heartflow's 2027 annual shareholder meeting or the first anniversary of the grant date, contingent on continued service.
• The options have an expiration date of June 16, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard compensation event for a director rather than a significant financial event for the company.

Positives

• Director compensation through stock options aligns management's interests with shareholders.
• The grant of options suggests confidence in the company's future performance and share price appreciation.

Negatives

• The acquisition of options is a standard compensation practice and does not inherently represent new capital for the company.

Risks

• The value of the stock options is contingent on the future performance of Heartflow's stock price.
• Vesting is subject to continued service, meaning departure from the company before vesting would result in forfeiture.

Future Outlook

The vesting schedule for the stock options indicates a forward-looking expectation of continued service and potential company growth leading up to the 2027 annual meeting and the first anniversary of the grant date.

Industry Context

StockSavvy.ai notes that the issuance of stock options to directors is a common practice across the biotechnology and medical device sectors, aligning executive incentives with shareholder value creation. This aligns with industry norms for attracting and retaining key leadership.

Comparison to Industry Standards

• The structure of the stock option grant, including vesting tied to continued service and a specific expiration date, is standard practice for publicly traded companies in the healthcare technology sector.
• Many companies in this industry utilize similar equity-based compensation to incentivize long-term performance and retention of directors and executives.

Stakeholder Impact

• Shareholders: The alignment of director compensation with stock performance can be viewed positively, as it incentivizes decisions that may benefit shareholders.
• Employees: This transaction does not directly impact employees but reflects the company's compensation strategy for its board.
• Management: Julie A. Cullivan has a vested interest in the company's success due to the stock options granted.

Next Steps

• Continued service by Julie A. Cullivan through the vesting dates.
• Monitoring of Heartflow's stock performance relative to the option exercise price.

Key Dates

Keywords

Heartflow, HTFL, Form 4, Stock Options, Insider Trading, Director Compensation, SEC Filing, Equity Award